摘要
目的 研究贝伐珠单抗联合TP化疗方案治疗晚期宫颈癌的临床疗效及安全性。方法 选取2020年1月—2022年1月台州市立医院收治的100例晚期宫颈癌患者,随机分为对照组(50例,TP化疗方案治疗)以及观察组(50例,贝伐珠单抗联合TP化疗方案治疗)。比较两组患者治疗前后的肿瘤标志物[血管内皮生长因子(VEGF)、鳞状细胞癌抗原(SCCA)]、免疫功能、生活质量及情绪状态评分,并比较两组患者疗效及不良反应发生情况。结果 观察组患者治疗总有效率(82.00%)高于对照组(64.00%),差异有统计学意义(χ^(2)=4.110,P<0.05)。治疗后,观察组患者血清VEGF[(302.35±108.51)ng/L]、SCCA[(3.14±1.02)μg/L]水平均低于对照组[(398.33±128.67)ng/L、(5.25±1.22)μg/L],差异均有统计学意义(t=4.032、9.382,均P<0.05)。治疗后,观察组CD3^(+)[(64.32±4.58)%]、CD4^(+)[(47.48±4.29)%]、CD4^(+)/CD8^(+)(1.60±0.14)水平均高于对照组[(60.49±5.15)%、(42.95±4.33)%、(1.41±0.23)],差异均有统计学意义(t=3.390、5.063、4.490,均P<0.05)。治疗后,观察组自我感受负担量表(SPBS)评分[(47.45±2.08)分]低于对照组[(53.33±2.64)分],宫颈癌生活质量评价量表(FACT-Cx)评分[(95.97±4.32)分]高于对照组[(83.32±5.41)分],差异均有统计学意义(t=12.378、10.811,均P<0.05)。观察组不良反应发生率(20.00%)与对照组(10.00%)比较差异无统计学意义(χ^(2)=2.524,P>0.05)。结论 贝伐珠单抗联合TP化疗方案治疗晚期宫颈癌的疗效确切,能够有效增强患者免疫功能,改善生活质量及情绪,且未明显增加患者不良反应。
Objective To study the clinical efficacy and safety of bevacizumab combined with TP chemotherapy in treatment of ad⁃vanced cervical cancer.Methods A total of 100 patients with advanced cervical cancer admitted to Taizhou Municipal Hospital from January 2020 to January 2022 were selected and randomly divided into control group(50 cases,treated with TP chemotherapy regimen)and observa⁃tion group(50 cases,treated with bevacizumab combined with TP chemotherapy regimen).The tumor markers[vascular endothelial growth factor(VEGF),squamous cell carcinoma antigen(SCCA)],immune function,quality of life,and emotional state scores before and after treatment in the two groups were compared,and the efficacy and incidence rates of adverse reactions were compared between the two groups.Results The total effective rate of treatment in observation group(82.00%)was higher than that in control group(64.00%),and the difference was statistically significant(χ^(2)=4.110,P<0.05).After treatment,serum VEGF[(302.35±108.51)ng/L]and SCCA[(3.14±1.02)μg/L]levels in observation group were lower than those in control group[(398.33±128.67)ng/L,(5.25±1.22)μg/L],the differences were statistically significant(t=4.032,9.382,all P<0.05).After treatment,CD3^(+)[(64.32±4.58)%],CD4^(+)[(47.48±4.29)%],and CD4^(+)/CD8^(+)(1.60±0.14)in observation group were higher than those in control group[(60.49±5.15)%,(42.95±4.33)%,(1.41±0.23)],and the differences were statistically significant(t=3.390,5.063,4.490,all P<0.05).After treatment,self-perceived burden scale(SPBS)score(47.45±2.08)in observation group was lower than that in control group(53.33±2.64),cervical cancer quality of life assessment scale(FACT-Cx)score(95.97±4.32)was higher than that in control group(83.32±5.41),with statistically significant differences(t=12.378,10.811,P<0.05).There was no statistically significant difference in incidence rate of adverse reactions between observation group(20.00%)and control group(10.00%)(χ^(2)=2.524,P>0.05).Conclusion The com⁃bination of be
作者
应灵潇
柴芝红
YING Ling-xiao;CHAI Zhi-hong(Taizhou Municipal Hospital,Taizhou,Zhejiang 318000,China)
出处
《中国妇幼保健》
CAS
2024年第19期3685-3688,共4页
Maternal and Child Health Care of China
基金
教育部产学合作协同育人项目(220604408300411)
浙江省医药卫生科技计划项目(2022PY104)。
关键词
贝伐珠单抗
TP化疗方案
晚期宫颈癌
临床疗效
安全性
Bevacizumab
TP chemotherapy regimen
Advanced cervical cancer
Clinical efficacy
Security
